Incidence and spatial distribution of Chronic Myeloid Leukemia by regions of economic development in the state of Pernambuco, Brazil

Abstract

Background The establishment of regional development poles in the State of Pernambuco, Brazil was characterized by industrial expansion and consequent concerns about the increase in the occurrence of diseases, specifically those having long latency periods, as is the case of Chronic Myeloid Leukemia. Methods The study included 367 patients diagnosed with Chronic Myeloid Leukemia over a ten-year period at a reference treatment center. Records of patient charts and the TerraView software were used, respectively, for data collection and geographic mapping of the cases from the twelve established State development regions. Results A total incidence of 3.4 cases per 100,000 inhabitants was found, with a predominance of the disease among males, a median age of 47 years, a mestizo ethnicity, with elementary schooling and residence in urban area. Microregional incidence varied, but there was no significant variation in numbers over the years, and no relevant socio-environmental determinants were identified. Conclusion The present study determined the incidence and characterized the spatial distribution of Chronic Myeloid Leukemia cases over a decade in a northeastern Brazilian state. The variation in the incidence rate by region of development is compatible with a homogeneous distribution of the cases. The work is a baseline study to be used for present and future analyses of the impact of the state economic development poles and the occurrence of this chronic malignant disease.

Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France

“…The incidence rate found in our study is within the range of population-based reports from Sweden, southeast England, the United Kingdom, Taiwan, and in a recently published study on CML patients in 20 European countries ( Table 4 ). The incidence rates in these studies varied between 0.70 and 1.8/100,000 and the Surveillance, Epidemiology, and End Results (SEER) Program in the United States reported a remarkably high incidence of 1.75/100.000 ( 2 , 3 , 6 , 7 ). Our incidence rate is higher than previous estimates of the incidence in France which are between 0.95 and 1.14 per 100,000 person-years ( Table 4 ) ( 8 , 9 ).…”

“…or differences in study periods. However, the difference between different geographical areas and/or ethnical sub-groups cannot be excluded to explain these incidence variations ( 7 , 10 , 31 ).…”

Análise de mutações do domínio BCR-ABL quinase em pacientes com leucemia mielóide crônica refratários ao tratamento com mesilato de imatinibe

“…Nesse estudo, observamos predomínio da doença no sexo masculino (53%), com mediana de idade de 46 anos, semelhante aos achados de um grupo brasileiro no estado de Pernambuco, realizado com 367 pacientes diagnosticados com LMC, destes, 55% eram homens, com mediana de idade de 47 anos 19 . A maioria dos pacientes com LMC de países em desenvolvimento são mais jovens, quando comparado àqueles de países desenvolvidos.…”

“…A maioria dos pacientes com LMC de países em desenvolvimento são mais jovens, quando comparado àqueles de países desenvolvidos. Assim, o sexo e a idade de apresentação da doença parecem resultar de interações de fatores como estilo de vida, etnia, desenvolvimento do país e acesso a um diagnóstico de qualidade 12,[19][20][21] .…”

Deregulation of microRNAs expression and its role in Bcr-Abl+ cells resistance to TKI therapy

“…The median age at the diagnosis is usually 57 to 60 years in the general population but seems to be variable according to the studied region, comprising 66 years in the United States, 59 years in the United Kingdom, 56 years in France, and 57 years in Germany, for instance (HÖGLUND; SANDIN;SIMONSSON, 2015). In Brazil, the median age at the diagnosis is at least 10 years younger in comparison with the international statistics, ranging from 40 to 47 years old (BORTOLHEIRO;CHIATTONE, 2008;NEVES et al, 2019).…”